|
**Overview**: OncoPro OCA Plus PDL1 Panel**Introduction**: The OncoPro OCA Plus PDL1 Panel is a diagnostic tool designed for comprehensive tumor profiling using FFPE tissue. In India, advanced solid tumors require multi-gene and PD-L1 testing for precision therapy (TKIs for drivers, immunotherapy for high PD-L1). High morbidity from under-testing in rural/low-SES cancer patients, limited comprehensive labs, delayed targeted/immunotherapy leading to progression or toxicity from ineffective chemo. Per oncology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs PCR for tumor genomic profile and IHC for PD-L1 (22C3) expression over 1-2 days with high accuracy, valuable for broad actionable alteration detection. This diagnostic falls under cancer screening and targets patients with advanced solid tumors (lung, colorectal, melanoma), addressing accurate detection to guide personalized regimens. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise profiling and improving survival. Its FFPE-based approach ensures reliable genomic and expression analysis.**Other Names**: OCA Plus Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/oncology, compliant with 2025 standards.**Historical Milestone**: OCA Plus expanded profiling standard; in India, growing in precision centers.**Purpose**: The test assesses 2 parameters including tumor genomic profile to guide comprehensive cancer screening, detect alterations/PD-L1, inform targeted/immunotherapy.**Test Parameters**: 1. Tumor Genomic Profile, 2. PDL1 (22C3) Expression.**Pretest Condition**: No fasting required; patients should have tumor biopsy.**Specimen**: Formalin-fixed paraffin-embedded block (0.5â€"2 cm³), transported within specified times to maintain sample integrity.Sample Stability: Indefinite when properly stored in formalin/paraffin; testing possible long-term.**Medical History**: Patients should provide details on tumor type, stage, prior therapy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected alterations including wrong therapy, benefits of profiling, and no additional discomfort (uses existing block).**Procedural Considerations**: The test involves sample processing using PCR/IHC by trained personnel to ensure accurate scoring and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Poor block quality, inadequate tumor content, or interpretation differences can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Actionable alteration or high PD-L1 indicates targeted/immunotherapy eligibility, necessitating specialist input.**Specialist Consultation**: Medical oncologists should be consulted for management.**Additional Supporting Tests**: Full NGS, tumor board review for confirmation.**Test Limitations**: Profile scope limited; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, Cancer Studies India 2023. |
